Doximity, OpenEvidence settle lawsuits over development of healthcare AI chatbot
A bitter lawsuit between Doximity and OpenEvidence in a rivalry over creating a “ChatGPT for Doctors” has ended in a settlement, including the dismissal of all claims of corporate espionage and defamation, with prejudice.
The settlement was revealed in court filings on Friday, with each company also agreeing to absorb their own attorneys’ fees, per the order of a U.S. District Court in the District of Massachusetts judge.
The details of the settlement have not been disclosed and neither company has made a public statement.
HealthExec reached out to both for more information and will update this story with any statement we receive.
A war of AIs
The legal dispute between the two companies dates back to summer 2025, when OpenEvidence first sued Doximity, accusing the medical professional networking service of stealing its proprietary code, which it was allegedly using to build an AI model to support clinical decision making.
At the time OpenEvidence had received major financial backing from Sequoia Capital and Google Ventures to develop an AI chatbot catered to healthcare, something Doximity was in direct competition with.
Doximity was then, and continues, to be in partnership with OpenAI, the developer of ChatGPT for its model—Doximity GPT, a healthcare-dedicated version of the popular consumer chatbot. The idea was to create an artificial intelligence application that patients could rely on to answer medical questions, backed by research and feedback from real clinicians.
Meanwhile OpenEvidence was working to develop a system that would draw answers from clinical research, boasting partnerships with New England Journal of Medicine and JAMA.
OpenEvidence considered itself ahead of the game, however—so much so that it accused another AI company in February 2025, Pathway Medical of stealing its trade secrets.
The nature of the alleged espionage was nontraditional. OpenEvidence believed these spies were IT experts using prompt injection attacks against its AI chatbot—a technique designed to trick the AI into breaking its programming and to reveal secrets for how it operates.
Doximity then acquired Pathway Medical in August 2025 for $63 million, which OpenEvidence believed effectively gave Doximity access to the allegedly stolen secrets resulting from the prompt attacks.
OpenEvidence also believed Doximity then used the information to improve its other models. The company denied the allegations, filing a counter lawsuit accusing OpenEvidence of spreading misinformation in an effort to damage Doximity and hire valuable talent for the development of the ultimate medical AI chatbot.
In reporting on the conflict in September 2025, Business Insider said the lawsuit actually dated back to February, when OpenEvidence sued Pathway Medical. As the outlet noted, the dispute was a first for the legal system, new to addressing issues such as prompt attacks as a possible form of espionage and stealing trade secrets.
It’s unclear if any of those central issues are resolved at all, given the out of court settlement.
For now, the dispute appears to be resolved.
Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.